Etoposide Sensitizes CT26 Colorectal Adenocarcinoma to Radiation Therapy in BALB/c Mice

    Chia-Yuan, Liu, Hui-Fen, Liao, Tsang-En, Wang, Shee-Chan, Lin Lin, Shou-Chuan, Shih, Wen-Hsuing, Chang, Yuh-Cheng, Yang Yang, Ching-Chung, Yu-Jen, Chen
    Studysummary This study found that etoposide enhances the radiosensitivity of CT26 colorectal adenocarcinoma in BALB/c mice, significantly inhibiting tumor growth without significant toxicity.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study investigated the effect of combining etoposide with radiation therapy (RT) on CT26 colorectal adenocarcinoma in BALB/c mice. Mice were divided into four groups: control, etoposide, RT, and combination therapy. Results showed that tumor growth was significantly inhibited by both RT and the combination therapy, with the combination therapy being more effective than RT alone. There were no significant changes in body weight, plasma alanine aminotransferase, or creatinine levels across the groups. Although leukocyte counts decreased significantly in the RT and combination therapy groups, this effect was transient. Importantly, no skin changes or hair loss were observed. The study concluded that etoposide effectively sensitized the tumors to RT without causing significant toxicity.
    Discuss this study in the Community →